



NATIONAL





P200

Importance of Biobanks for Translational Cancer Research in Serbia

Ana Djuric¹, Miljana Tanic¹, Snezana Bjelogrlic¹, Mladen Marinkovic^{2,3}, Aleksandra Stanojevic¹, Jelena Spasic⁴, Suzana Stojanovic-Rundic^{2,3}, Radmila Jankovic¹, Ana Krivokuca⁵, Katarina Mirjacic Martinovic¹, Ana Vuletic¹, Marija Djordjic Crnogorac⁵, Ana Damjanovic¹, Marko Radulovic¹, Remond Fijneman⁶, Jerome Zoidakis^{7,8}, Sergi Castellví-Bel⁹, Milena Cavic¹

Department of Experimental Oncology, Institute for Oncology and Radiology of Serbia, Belgrade, Serbia ²Clinic for Radiation Oncology and Diagnostics, Department of Radiation Oncology, Institute for Oncology and Radiology of Serbia, Belgrade, Serbia

³Faculty of Medicine, University of Belgrade, Belgrade, Serbia

⁴Clinic for Medical Oncology, Institute for Oncology and Radiology of Serbia, Belgrade, Serbia

Introduction: Implementing good biobanking practice (GBP) and promoting interdisciplinary collaborations between healthcare professionals, scientists, patients, and industry stakeholders might play a pivotal role in the rapid translation of cutting-edge scientific discoveries into clinical practice. Following the GBP principles, we aimed to establish a workflow for the first Rectal Cancer Biobank (RCB) at the Institute for Oncology and Radiology of Serbia (IORS) within the framework of the Horizon Europe STEPUPIORS project.

Material and Methods: The workflow for the RCB was set up according to guidelines provided by relevant international authorities and national and EU regulations and monitored by higher partner institutions from Spain, the Netherlands and Greece. Biobank equipment and Laboratory Information Management Software (LIMS) were procured to ensure infrastructural, storage and data protection requirements. Human capacities were built through relevant training and expert visits to partner institutions. All decisions were approved by a consensus of the partner consortium.

Results: Within the first year, the STEPUPIORS team established the procedures for the first RCB of around 100 patients with locally advanced rectal cancer. Fifteen IORS personnel (5 physicians, 3 biochemists, 4 molecular biologists, 3 pharmacists) were successfully trained in biobanking. Thirteen standard operating procedures (SOPs) were implemented to comply with GBP. Scientific and management oversight committees comprised of members of all participating institutions were formed. A strengths, weaknesses, opportunities and threats (SWOT) analysis was performed as a starting point for developing sustainable biobanks at IORS and Serbia in the future. The IORS RCB was fully operational on October 01, 2023, when the prospective collection of tissue, plasma and sample derivatives was initiated for the current and three new planned projects.

Conclusions: Implementing the principles of GBP and promoting interdisciplinary collaborations is expected to ensure that innovative diagnostic tools and therapies reach patients more rapidly, contributing to the principles of circular bioeconomy.

Key words: biobank, rectal cancer, translational cancer research.

Acknowledgements

This study was funded by the Horizon Europe Twinning Project STEPUPIORS (Agreement No. 101079217) and the Ministry of Education and Science of the Republic of Serbia (Agreement No. 451-03-47/2023-01/200043).

⁵Department of Genetic Counseling for Hereditary Cancers, Institute for Oncology and Radiology of Serbia, Belgrade, Serbia

⁶Department of Pathology, The Netherlands Cancer Institute - Antoni van Leeuwenhoekziekenhuis, Amsterdam, the Netherlands

⁷Department of Biotechnology, Biomedical Research Foundation, Academy of Athens, Athens, Greece

⁸Department of Biology, National and Kapodistrian University of Athens, Athens, Greece

⁹Gastroenterology Department, Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Hospital Clínic, University of Barcelona, Barcelona, Spain